RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
Seeking Alpha11/4/2026Neutral
RXST
Rxsight IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$190.36M
P/E Ratio
—
EPS
$-1.29
Beta
1.19
52W High
$13.22
52W Low
$4.11
50-Day MA
$5.27
200-Day MA
$6.26
Dividend Yield
—
Profit Margin
-43.80%
Forward P/E
116.28
PEG Ratio
—
About Rxsight Inc
Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.
Fundamentals
| Revenue (TTM) | $121.83M |
| Gross Profit (TTM) | $92.75M |
| EBITDA | $-57.84M |
| Operating Margin | -75.30% |
| Return on Equity | -20.10% |
| Return on Assets | -11.80% |
| Revenue/Share (TTM) | $2.94 |
| Book Value | $6.08 |
| Price-to-Book | 0.74 |
| Price-to-Sales (TTM) | 1.56 |
| EV/Revenue | 0.0112 |
| EV/EBITDA | -7.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -19.00% |
| Shares Outstanding | $41.93M |
| Float | $34.87M |
| % Insiders | 6.52% |
| % Institutions | 101.43% |
Historical Volatility
HV 10-Day
74.28%
HV 20-Day
62.24%
HV 30-Day
54.14%
HV 60-Day
54.32%
HV Rank
12.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.57 target)
1
Strong Buy7
Hold2
Strong SellLatest News
What RxSight (RXST) Said on Its Q3 Earnings Call
RxSight NASDAQ: RXST reported third-quarter revenue of $24.6 million, down 19% from $30.3 million a year earlier, as the company faced competitive pressure, seasonal effects and disruption tied to a commercial restructuring and sales-force expansion.
MarketBeat11/4/2026Neutral
RxSight, Inc. Reports Third Quarter 2026 Results
ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire11/3/2026Neutral
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire10/20/2026Neutral
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
GlobeNewsWire10/16/2026Neutral
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
GlobeNewsWire8/26/2026Neutral
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
RxSight Q2 Earnings Call Highlights
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
MarketBeat8/6/2026Positive
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.
GlobeNewsWire8/5/2026Neutral
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/29/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RXST and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026